AHERF EV Biofoundry — Diagnostics to CommercializationEV BiofoundryCliniConnectEV-Qual™ServicesStart an Enquiry
Access

CliniConnect: the clinical front door for translational research

AHERF-CMBRC enables clinicians and departments to enter with a clinical question, test feasibility, connect with a disease consortium and route the work to the right EV, biomarker, liquid biopsy or Clinical AI platform.

Submit a clinical questionJoin a clinical consortium
Structured submission

Capture the clinical question, department, disease context, cohort idea and expected translational output.

Feasibility scoping

Review sample type, metadata, ethics pathway, clinical relevance and platform fit before execution.

Platform mapping

Route the work to CliniConnect, EV-Works, EV-Qual, Biomarker Works, Clinical AI, services or collaboration.

Clinical entry through CliniConnect

Clinical Access centers on CliniConnect, a structured route for clinicians, departments and disease groups to enter the AHERF-CMBRC translational ecosystem.

Clinical consortiums
Active / proof-of-concept

Ophthalmology Consortium

Ocular biomarker, tear-derived EV and eye-linked systemic disease programs.

  • Pterygium
  • Diabetic retinopathy
  • Ocular hypertension, glaucoma, cataract and refractive disorders
  • Ocular surface disease
EV-WorksBiomarker WorksClinical AI
Active / platform-ready

Neurology Consortium

CNS biomarker, neuronal/CNS-enriched EV and brain-health programs.

  • Alzheimer’s disease and dementia
  • Parkinson’s disease, MS, ALS and TBI
  • Brain ageing and neuroinflammation
EV-WorksEV-QualClinical AI
Program development

Reproductive Biology & Child Health Consortium

Reproductive, maternal, metabolic and pediatric biomarker programs.

  • Gestational diabetes
  • PCOS, infertility and IVF biomarker research
  • Pediatric metabolic, inflammatory and immune disorders
Biomarker WorksClinical AIGrants
Platform-ready / partner-seeking

Oncology Consortium

Cancer-focused liquid biopsy, tumor-derived EV and therapy-response biomarker programs.

  • Oral, prostate, breast and renal cancers
  • Brain tumors and other solid tumors
  • Recurrence, residual disease and companion diagnostic exploration
Liquid BiopsyEV-WorksServices
Program development

Renal & Metabolic Consortium

Kidney injury, graft rejection, diabetic nephropathy and metabolic-risk biomarker programs.

  • Kidney graft rejection
  • Diabetic nephropathy and CKD
  • Renal inflammation, fibrosis and immune activation
Urinary EVsBiomarker WorksClinical AI
Cross-cutting platform

Precision Medicine & Liquid Biopsy Consortium

Cross-disease liquid biopsy and multimodal integrated risk models.

  • EV + cfDNA + protein + transcript panels
  • Clinical and imaging metadata integration
  • AI-enabled risk scores and longitudinal models
Clinical AILiquid BiopsyEV-Qual
Clinical Consortia under CliniConnect

All disease consortia are coordinated through CliniConnect. Each consortium begins with a clinically relevant question, defined cohort and biospecimen route, metadata plan, ethics pathway and Biofoundry mapping.

Active / proof-of-concept

Ophthalmology Consortium

Ocular biomarker, tear-derived EV and eye-linked systemic-disease programs.

  • Pterygium.
  • Diabetic retinopathy.
  • Ocular hypertension and glaucoma.
  • Cataract and refractive disorders.
  • Ocular surface disease.
EV WorksEV-Qual™Tear EV workflowsBiomarker panels
Active / platform-ready

Neurology Consortium

CNS biomarker, neuronal or CNS-enriched EV and brain-health programs.

  • Alzheimer’s disease and dementia.
  • Parkinson’s disease.
  • Multiple sclerosis and ALS / motor neuron disease.
  • Traumatic brain injury.
  • Brain ageing and neuroinflammation.
  • Glioma and other CNS tumors.
EV WorksEV-Qual™Liquid biopsyLongitudinal biomarkers
Program development

Reproductive Biology & Child Health Consortium

Reproductive, maternal, metabolic and pediatric biomarker programs.

  • Gestational diabetes.
  • PCOS and endometriosis.
  • Infertility and IVF biomarker research.
  • Pregnancy-associated metabolic risk.
  • Pediatric metabolic, inflammatory and immune disorders.
CliniConnectBiomarker developmentEV workflowsGrant development
Platform-ready / partner-seeking

Oncology Consortium

Cancer-focused liquid biopsy, tumor-derived EV and treatment-response biomarker programs.

  • Oral and head-and-neck cancers.
  • Prostate cancer.
  • Breast and renal cancers.
  • Brain tumors and other solid tumors.
  • Early detection, recurrence and residual-disease monitoring.
  • Therapy-response and companion-diagnostic exploration.
Liquid biopsyEV WorksMolecular panelsValidation pathway
Program development

Renal & Metabolic Consortium

Kidney injury, graft rejection, diabetic nephropathy and metabolic-risk biomarker programs.

  • Kidney graft rejection and surveillance.
  • Diabetic nephropathy and chronic kidney disease.
  • Renal inflammation, fibrosis and immune activation.
  • Diabetes, insulin resistance and metabolic syndrome.
  • Obesity-linked risk, MASLD and cardiometabolic models.
Urinary EVsBiomarker panelsEV-Qual™Longitudinal monitoring
Emerging program

Infectious Disease & Immunology Consortium

Host-response biomarkers, immune monitoring, infection-associated inflammation and assay-development programs.

  • Host-response signatures.
  • Immune activation and immune-monitoring panels.
  • Infection-associated inflammatory markers.
  • Vaccine-response and immunomodulation research.
ImmunologyEV workflowsBiomarker developmentTranslational assays
How CliniConnect works: Submit clinical question → Join relevant consortium → Feasibility discussion → Link to AHERF-CMBRC platform.

Bring a clinical question into CliniConnect

Use this route when a clinician, department or disease group wants to enter the AHERF-CMBRC translational ecosystem through a consortium-led route.

Submit a clinical questionJoin a consortiumContact AHERF-CMBRC